AZD4144

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

SepsisHepatic Impairment

100 competitors in Sepsis

#DrugCompanyPhaseTrials

1

Gleevec

Novartis

Phase 2

12

Antibiotics

MMelinta Therapeutics, Inc.

Phase 3

23

N-Acetylcysteine (NAC) Treatment

TThe First Affiliated Hospital of Soochow University

Phase 3

14

Decadron

AAspen Global Incorporated

Phase 2

15

Nafamostat Mesylate

EEnsysce Biosciences

Phase 3

26

Hydrocortisone Administration

UUniversity of Virginia

Phase 3

17

Simdax

Orion Corporation, Orion Pharma

Preclinical

18

Zyvox

Pfizer

Preclinical

—9

Zemplar

AbbVie

Preclinical

—10

Primaxin

Pfizer

Preclinical

—Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Statin2 trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06491550·91 enrolled

A Study to Investigate How AZD4144 Affects the Pharmacokinetics of Rosuvastatin in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06925854·12 enrolled

Tics1 trial

A Study to Investigate the Relative Bioavailability of 2 Different Formulations of AZD4144, the Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06948006·32 enrolled

Chronic Kidney Disease1 trial

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

Completed·AstraZeneca·Phase 1·NCT06675175·29 enrolled

Obesity1 trial

A Study to Investigate the Safety, Tolerability and Pharmacodynamics of AZD4144 in Participants With Obesity

Completed·AstraZeneca·Phase 1·NCT06942923·28 enrolled

Kidney Disease1 trial

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06693765·41 enrolled

4 more indications

Oral1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Completed·AstraZeneca·Phase 1·NCT06122714·95 enrolled

Sepsis1 trial

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)

Recruiting·AstraZeneca·Phase 2·NCT07215702·124 enrolled

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144

Not yet recruiting·AstraZeneca·Phase 1·NCT07783308·30 enrolled

Unspecified1 trial

An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to Assess the Pharmacokinetics of AZD4144 When Administered Alone and in Combination With Itraconazole

Completed·AstraZeneca·Phase 1·NCT07685600·32 enrolled

Details

Drug Info

Related News